Evaluation of tumor affinity of mono-[123I]iodohypericin and mono-[123I]iodoprotohypericin in a mouse model with a RIF-1 tumor

Contrast Media and Molecular Imaging

Volumn 2, Issue 3, 2007, Pages 113-119

  Fonge, Humphrey ^a   Van de Putte, Marie ^a   Huyghe, Dieter ^a   Bormans, Guy ^a   Ni, Yicheng ^b   de Witte, Peter ^a   Verbruggen, Alfons ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Biodistribution; Mono 123I iodohypericin; Mono 123I iodoprotohypericin; Radiodiagnosis

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HYPERICIN; LOW DENSITY LIPOPROTEIN; MONOIODOHYPERICIN; MONOIODOHYPERICIN I 123; MONOIODOPROTOHYPERICIN; MONOIODOPROTOHYPERICIN I 123; QUINONE DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; DRUG TRANSPORT; DRUG UPTAKE; ENDOCYTOSIS; FEMALE; FIBROSARCOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIODIAGNOSIS;

ANIMALS; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; FIBROSARCOMA; IODINE RADIOISOTOPES; LIPOPROTEINS, LDL; MICE; MICE, INBRED C3H; MODELS, CHEMICAL; NEOPLASM TRANSPLANTATION; PERYLENE; RADIOACTIVE TRACERS; TISSUE DISTRIBUTION;

EID: 34547538159     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.136     Document Type: Article

References (24)

1. Falk H, Meyer J, Oberreiter M. A convenient semisynthetic route to hypericin. Monatsh. Chem. 1993; 124: 339-341.
2. Lavie G, Mazur Y, Lavie D, Meruelo D. The chemical and biological properties of hypericin - a compound with a broad-spectrum of biological-activities. Med. Res. Rev. 1995; 15: 111-119.
3. Kamuhabwa A, Agostinis P, Ahmed B, Landuyt W, Van Cleynenbreugel B, Van Poppel H, de Witte P. Hypericin as a potential phototherapeutic agent in superficial transitional cell carcinoma of the bladder. Photochem. Photobiol. Sci. 2004; 3: 772-780.
4. Cavarga I, Brezani P, Cekanova-Figurova M, Solar P, Fedorocko P, Migkovsky P. Photodynamic therapy with topical and systemic murine fibrosarcoma administration of hypericin. Phytomedicine 2001; 8: 325-330.
5. Chen B, de Witte PA. Photodynamic therapy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor model. Cancer Lett. 2000; 150: 111-117.
6. Chen B, Xu Y, Roskams T, Delaey E, Agostinis P, Vandenheede JR, de Witte P. Efficacy of antitumoral photodynamic therapy with hypericin: Relationship between biodistribution and photodynamic effects in the R1F-1 mouse tumor model. Int. J. Cancer 2001; 93: 275-282.
7. Blank M, Lavie G, Mandel M, Hazan S, Orenstein A, Meruelo D, Keisari Y. Antimetastatic activity of the photodynamic agent hypericin in the dark. Int. J. Cancer 2004; 111: 596-603.
8. Blank M, Mandel M, Keisari Y, Meruelo D, Lavie G. Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res. 2003; 63: 8241-8247.
9. Van De Putte M, Roskams T, Bormans G, Verbruggen A, De Witte PA. The impact of aggregation on the biodistribution of hypericin. Int. J. Oncol. 2006; 28: 655-660.
10. Jori G, Reddi E. The role of lipoproteins in the delivery of tumor-targeting photosensitizers. Int. J. Biochem. 1993; 25: 1369-1375.
11. Bormans G, Huyghe D, Christiaen A, Verbeke K, de Groot T, Vanbilloen H, de Witte P, Verbruggen A. Preparation, analysis and biodistribution in mice of iodine-123 labelled derivatives of hypericin. J. Labelled Compd Radiopharm. 2004; 47: 191-198.
12. Kessel D, Woodburn K. Biodistribution of photosensitizing agents. Int. J. Biochem. 1993; 25: 1377-1383.
13. Lavie G, Mazur Y, Lavie D, Prince AM, Pascual D, Liebes L, Levin B, Meruelo D. Hypericin as an inactivator of infectious viruses in blood components. [See comment.] Transfusion 1995; 35: 392-400.
14. Gotto AM, Pownall HJ, Havel RJ. Introduction to the plasma lipoproteins. In Methods in Enzymology, Segrest JP, Albers JJ (eds). Academic Press: New York, 1986; 3-41.
15. Maziere JC, Santus R, Morliere P, Reyftmann JP, Candide C, Mora L, Salmon S, Maziere C, Gatt S, Dubertret L. Cellular uptake and photosensitizing properties of anticancer porphyrins in cell-membranes and low and nigh-density lipoproteins. J. Photochem. Photobiol. B Biol. 1990; 6: 61-68.
16. Allison BA, Pritchard PH, Richter AM, Levy JG. The plasma distribution of benzoporphyrin derivative and the effects of plasma lipoproteins on its biodistribution. Photochem. Photobiol. 1990; 52: 501-507.
17. Reddi E, Zhou C, Biolo R, Menegaldo E, Jori G. Liposome- or LDL-administered Zn (II)-phthalocyanine as a photodynamic agent for tumours. I. Pharmacokinetic properties and phototherapeutic efficiency. Br. J. Cancer 1990; 61: 407-411.
18. Van de Putte M, Roskams T, Vandenheede JR, Agostinis P, de Witte PA. Elucidation of the tumoritropic principle of hypericin. Br. J. Cancer 2005; 92: 1406-1413.
19. 123I]iodohypericin as a necrosis-avid tracer agent. Eur. J. Nucl. Med. Mol. Imag. 2006; 33: 595-601.
20. 2 ligands. In Technetium and Rhenium in chemistry and nuclear medicine, Nicolini M, Bandoli G, Mazzi U (eds). Cortina International: 1989; 475-502.
21. Hopkinson HJ, Vernon DI, Brown SB. Identification and partial characterization of an unusual distribution of the photosensitizer meta-tetrahydroxyphenyl chlorin (temoporfin) in human plasma. Photochem. Photobiol. 1999; 69: 482-488.
22. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 1955; 34: 1345-1353.
23. Twentyman PR, Brown JM, Gray JW, Franko AJ, Scoles MA, Kallman RF. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J. Natl Cancer Inst. 1980; 64: 595-604.
24. 996mTc-N, N′-bis-(mercaptoacetamido) ethylenediamine. Effect of renal tubular transport inhibitors. Int. J. Nucl. Med. Biol. 1982; 9: 79-82.